Oncoinvent ASA: Grant of share options to new Chief Medical Officer

Oslo, Norway, 28 October 2026: Oncoinvent has granted the new Chief Medical
Officer (CMO) Dr Zuzana Jirakova Trnkova 20,000 share options in the Company
under the Company's long term incentive program, each with a strike price of NOK
67.35, equal to the volume weighted average share price the last day before the
grant. See the attached form. Following the grant of the 20,000 share options
referred to above, Zuzana Jirakova Trnkova holds 20,000 options in the Company.

Each option, when exercised, will give the right to acquire one share in the
Company. The options are granted without consideration. No Options shall vest
during the first 12 months following the date of the Grant Letter, 13/48 of the
Options shall vest in the 13th month, and the remaining Options shall thereafter
vest in equal monthly instalments of 1/48 (as long as the option holder is still
employed). Options that have not been exercised will lapse 7 years after the
date of grant.

The board considers an option program as an important element in attracting and
retaining employees to foster long-term success. The Board considers the option
program terms and allocation to be at the market for comparable peers.

PDMR Zuzana Jiráková
Trnková.pdf (https://mb.cision.com/Public/15728/4416272/84908ae2b0764c84.pdf)

This information is subject to the disclosure requirements pursuant to
Regulation (EU) 596/2014 (MAR) Article 19 and Section 5-12 of the Norwegian
Securities Trading Act.

For further information, please contact:

Oystein Soug, Chief Executive Officer
Email: IR@oncoinvent.com (soug@oncoinvent.com)

This information is published in accordance with article 19 of the EU Market
Abuse Regulation (MAR).

About Oncoinvent

Oncoinvent is developing Radspherin[®], a receptor-independent alpha radiation
therapy that leverages the unique anatomy of the abdominal cavity to destroy
residual micrometastases using a single, highly localized dose of alpha
radiation. The initial clinical focus is treatment of ovarian and colorectal
cancer patients after surgical removal of the primary tumor and visible
metastases in the peritoneum, the thin membrane lining the abdominal cavity and
covering the abdominal organs.

This radiopharmaceutical is designed to prevent or delay recurrence in the
peritoneal cavity, keeping patients disease-free for longer than the current
standard of care and thereby also impacting overall survival. It is broadly
applicable to any cancer that spreads to the peritoneum, e.g. ovarian,
colorectal, and gastric cancers. Radspherin[®] stands out for its simplicity,
excellent safety profile, and seamless integration into existing surgical
workflows. Oncoinvent's product is easy to use, avoids systemic delivery and
significant toxicity. It is also differentiated in being simple to manufacture,
scalable, and supply de-risked.

Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers
are highly promising, showing an excellent safety profile and meaningful signals
of efficacy. Interim data from an ongoing, randomized, controlled phase 2
ovarian cancer trial is expected in 2H2026 (safety) and 1H2027 (early efficacy).
With cost-effective manufacturing, blockbuster potential, active pharma
partnership momentum, plus strong endorsements from leading experts, Oncoinvent
is built for scale and commercial success, and is set to become the new standard
for post-surgical cancer care. The Company was founded by the originators of
Algeta and Xofigo (acquired by Bayer).
ancer care. The Company was founded by the originators of\
Algeta and Xofigo (acquired by Bayer).\